Terrible News for Pfizer Stock Investors
The past three years have been challenging for Pfizer (PFE 0.11%). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022. Although Pfizer has made some efforts to turn things around, they have been insufficient. And recent regulatory developments in the U.S. somewhat complicate things for the drugmaker. Here's what investors need to know. Regulators restrict access to the vaccine Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio. After producing record revenue thanks...



